- Home
- MUA vs ARDX Comparison
MUA vs ARDX Comparison
Compare MUA & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | ARDX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.0M | 797.8M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MUA | ARDX |
|---|---|---|
| Price | $9.77 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $12.80 |
| AVG Volume (30 Days) | 323.3K | ★ 4.3M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $19.21 |
| Revenue Next Year | N/A | $28.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.13 | $2.96 |
| 52 Week High | $11.26 | $8.40 |
Technical Indicators
Market Signals| Indicator | MUA | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 37.18 |
| Support Level | $9.62 | N/A |
| Resistance Level | $9.76 | $3.35 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 56.78 | 15.19 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.